Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data

Regeneron Pharmaceuticals has seen its share price move around in recent years, and fresh trial results plus a major immunology alliance are back in focus. With the stock closing at US$778.36 and investors watching new drug data closely, the open question is whether that price still lines up with what the business earns today. Over the past 5 years, Regeneron Pharmaceuticals has delivered a total return of 39.6%, which puts real pressure on the current earnings multiple to carry that...